2. UroToday Home
  3. Video Lectures

PSMA and Beyond Conference 2025 Videos

Comparing Post-Treatment SPECT to PSMA PET for Radioligand Therapy Monitoring "Presentation" - Thomas Hope
Improving Outcomes with Combination Therapies for PSMA Radioligand Treatment "Presentation" - Michael Hofman
FAP and Nectin-4 Targeted Imaging and Therapy in Urothelial Cancer "Presentation" - Vadim Koshkin
CA-IX Imaging in Kidney Cancer Detection and Characterization "Presentation" - Brian Shuch
Comparing Lead-212 and Actinium-225 Alpha Emitters for Prostate Cancer Treatment "Presentation" - Alfred Morgenstern
TROP2 as Alternative Target for Metastatic Prostate Cancer Imaging and Therapy "Presentation" - Tanya Stoyanova
Human Kallikrein Targeted Radioimmunotheranostics for Prostate Cancer Treatment "Presentation" - Hans David Ulmert
Beyond PSMA: Targets for Prostate Cancer Radiopharmaceutical Therapy "Presentation" - Robert Flavell
The Value of Animal Models in Evaluating PSMA-Targeted RPT and Non-RPT Therapies "Presentation" - Deborah Charych
Antibody-Drug Conjugates in Prostate Cancer Treatment "Presentation" - John Lee
GRPR Antagonists Beyond PSMA in Prostate Cancer Detection and Treatment "Presentation" - Andrei Iagaru
PSMA-Targeted Immunotherapy: CAR T and Bispecific T Cell Engagers "Presentation" - Tanya Dorff
Beyond Lutetium PSMA: Exploring Terbium-161 for Treatment-Resistant Prostate Cancer "Presentation" - Michael Hofman
Comparing PSMA-617 and PSMA-I&T Radiopharmaceuticals for Prostate Cancer Therapy "Presentation" - Matthias Eiber
Are We Optimally Dosing Patients with PSMA Radiopharmaceutical Therapy? "Presentation" - Amir Iravani
PSMA RLT: A Private Medical Oncology Delivery Model "Presentation" - Luke Nordquist
How Does PSMA RLT Kill Cells? Alpha vs Beta Radiobiology "Presentation" - Ana Ponce Kiess
Clinical Experience with Actinium-PSMA Across Multiple Treatment Centers "Presentation" - Alfred Morgenstern
Next-Generation PSMA Radioligands "Presentation" - Martin Pomper
Lessons from Radiation Oncology: How Can We Improve PSMA RLT? "Presentation" - Daniel Spratt
Dry Mouth Prevention and Management for PSMA Radioligand Therapy "Presentation" - Sue Yom
PSMA-Targeted Antibodies for Prostate Cancer Radioligand Therapy "Presentation" - Scott Tagawa
How are we Getting Paid for Theranostics and Dosimetry? "Presentation" - Denise Merlino
Beyond the 23 Gy Threshold: Renal Toxicity, EBRT, and RLT "Presentation" - Ana Ponce Kiess
PSMA RLT: Radiation Oncology and Health-System Perspective "Presentation" - Dustin Boothe
Reimagining PSMA Radioligand Therapy for Castration-Sensitive Prostate Cancer "Presentation" - Michael Morris
Lutetium PSMA Beyond Six Cycles Extended Treatment and Re-Challenge Approaches "Presentation" - Matthias Eiber
When Should We Use 18F-FDG PET? "Presentation" - Andrei Iagaru
Overview of Clinical Trials of PSMA RPT in 2025 "Presentation" - Jeremie Calais
Post-Treatment SPECT Imaging for Personalized Radiopharmaceutical Therapy "Presentation" - Carlos Uribe
AI Applications for Simplifying Radiopharmaceutical Dosimetry Workflows "Presentation" - Irène Buvat
Sequencing with RLT in mCRPC "Presentation" - Tanya Dorff
PSMA RLT for Oligometastatic Disease "Presentation" - Amar Kishan
Radiation Safety and Ecology: Comparison of Practices in the US and the World "Presentation" - Catherine Meyer
Post-VISION Real World Experience in the US: How is PSMA RLT Being Used? "Presentation" - Matthew Rettig
Lessons from Germany in Early Access PSMA Therapy in Clinical Practice "Presentation" - Wolfgang Fendler
Pre-chemo 177Lu-PSMA Trials: PSMAfore, SPLASH, and ECLIPSE "Presentation" - Emmanuel Antonarakis
How to Crush a PSMA PET Report: Guidelines and Scoring Systems "Presentation" - Phillip Kuo
Can We Kill the Bone Scan? "Presentation" - Daniel Spratt
PRIMARY Score and Where it Plays a Role in Prostate Cancer Diagnosis "Presentation" - Michael Hofman
The Changing Role of MRI in Staging Patients with Prostate Cancer "Presentation" - Steven Raman
Incorporating PSMA PET into Clinical Trials "Presentation" - Michael Morris
Can PSMA-Targeted Prostate Biopsy Detect Cancer When MRI-Guided Biopsy is Negative? "Presentation" - Wayne Brisbane
Role of PSMA PET in Surgical Planning and Post-Operative Management "Presentation" - Carissa Chu
Whole Body PSMA Quantitative Parameters: Why Are We Not Using Whole Body PSMA PET Parameters in the Real World? "Presentation" Irène Buvat
PSMA-PET for Overall Survival Outcomes Risk Stratification of Prostate Cancer "Presentation" - Wolfgang Fendler
Who Benefits from Oligometastasis Directed Therapy? "Presentation" - Julian Hong
Impact of Clinical Guidelines on PSMA-PET Implementation "Presentation" - Emmanuel Antonarakis
Pictoral Atlas of PSMA PET "Presentation" - Matthias Benz
Landscape of Approved and Upcoming PSMA Imaging Agents "Presentation" - Amir Iravani
PSMA Origins "Presentation" - Martin Pomper